Immler Dorian, Greven Simone, Reinemer Peter
Bayer Healthcare AG, PH-R&D-R-EU-ET, Wuppertal, Germany.
Proteomics. 2006 May;6(10):2947-58. doi: 10.1002/pmic.200500659.
Authentic biomarkers, distilling the essence of a complex, functionally significant process in a mammalian system into a precise, physicochemical measurement have been implicated as a tool of increasing importance for drug discovery and development. However, even in spite of recent technological advances, validating a new biomarker candidate, where generation of suitable antibodies is required, is still a long-lasting task. Methods to accelerate initial validation by MS approaches have been suggested, but all methods described so far are associated with serious drawbacks, finally leading to non-generic methods of detection and quantification. Moreover, when complex body fluids are used as samples, efficient debulking strategies are crucial to open a window of analytical sensitivity in the ng/mL range, where many diagnostically relevant analytes are present. Here we report the proof-of-principle of a multi-dimensional strategy for accelerated initial validation of biomarker candidates by MS, which promises to be generally applicable, sensitive and quantitative. The method presented employs a combination of electrophoretic and chromatographic steps on the peptide level, followed by MS quantification using isotopically labeled synthetic peptides as internal standards. Our proposed workflow includes up to four dimensions, finally resulting in a desired LOD sufficient to detect and quantify diagnostically relevant analytes from complex samples. Although the current state of the method only represents a starting point for further validation and development, it reveals great potential in biomarker validation.
真正的生物标志物,即将哺乳动物系统中复杂且具有功能重要性的过程的本质提炼为精确的物理化学测量值,已被视为在药物发现和开发中日益重要的工具。然而,即使尽管有近期的技术进步,但验证一个需要生成合适抗体的新生物标志物候选物仍然是一项长期任务。已有人提出通过质谱方法加速初始验证的方法,但迄今为止所描述的所有方法都存在严重缺陷,最终导致非通用的检测和定量方法。此外,当使用复杂体液作为样本时,有效的去冗余策略对于打开在纳克/毫升范围内的分析灵敏度窗口至关重要,在该范围内存在许多与诊断相关的分析物。在此,我们报告了一种通过质谱加速生物标志物候选物初始验证的多维策略的原理证明,该策略有望具有普遍适用性、灵敏性和定量性。所提出的方法在肽水平上采用电泳和色谱步骤的组合,随后使用同位素标记的合成肽作为内标进行质谱定量。我们提出的工作流程包括多达四个维度,最终产生足以从复杂样本中检测和定量与诊断相关的分析物的所需检测限。尽管该方法的当前状态仅代表进一步验证和开发的起点,但它在生物标志物验证方面显示出巨大潜力。